AI assistant
AVADEL PHARMACEUTICALS PLC — Director's Dealing 2025
Mar 7, 2025
31920_dirs_2025-03-07_41845a92-9624-454d-90e6-3c1027d30427.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AVADEL PHARMACEUTICALS PLC (AVDL)
CIK: 0001012477
Period of Report: 2025-03-05
Reporting Person: Divis Gregory J (Director, Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-03-05 | Ordinary Shares | A | 52000 | — | Acquired | 211100 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-03-05 | Stock Option (Right to Buy) | $7.87 | A | 310000 | Acquired | 2030-03-06 | Ordinary Shares (310000) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Ordinary Shares | 10000 | Indirect |
Footnotes
F1: Consists of a restricted share award. The restricted share award shall vest in equal annual installments on each of the first four anniversaries following the 3/5/2025 grant date.
F2: These Ordinary Shares are held by the Gregory J. Divis Jr. Revocable Trust, of which the Reporting Person is trustee and beneficiary.
F3: The options shall vest, if at all, in four equal increments if the volume-weighted average price of the Issuer's Ordinary Shares during any 30 calendar day period exceeds $11, $14, $17 and $19.09, respectively.